Clinical trials: COMBO Condition
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01644175
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 76 sites in United States
- Volunteers
- 316 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice
This was a single-arm, multicenter, open label, prospective cohort study (post-marketing observational study) to determine the effectiveness and safety of adalimumab in combination with high-dose methotrexate (≥12 mg/week) in…
- Trial name
- NCT01736189
- Testing
- Adalimumab
- Volunteers
- 346 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Age-Related Macular Degeneration, Choroidal Neovascularization
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
- Trial name
- 20089/Combo (NCT01175395)
- Testing
- IBI-20089/Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt
This is a multi-center, single-blind, randomized, active-controlled, clinical trial in Percutaneous Coronary Intervention (PCI) subjects.
- Trial name
- HARMONEE (NCT02073565)
- Testing
- OrbusNeich Combo stent™, Everolimus Eluting Stent (EES)
- Where
- 50 sites in United States, Japan
- Volunteers
- 572 people
- Sponsor
- OrbusNeich
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Bilateral Blepharitis (Disorder)
To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis
The purpose of this study is to evaluate the efficacy of, and patient satisfaction with Blephapad Combo in the treatment of posterior blepharitis.
- Trial name
- NCT03301844
- Testing
- Blephapad Combo, Standard treatment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- NTC srl
Chronic Pain
Fast-Acting Subperception Study (FAST)
Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain
- Trial name
- FAST (NCT04231409)
- Testing
- Boston Scientific Spectra WaveWriter SCS System
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Boston Scientific Corporation
Melanoma, Lymph Node Cancer
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
- Trial name
- NCT03618641
- Testing
- CMP-001, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Diwakar Davar
Type 2 Diabetes Mellitus
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.
- Trial name
- NCT03861039
- Testing
- Tirzepatide, Oral antihyperglycemic medication (OAM)
- Where
- 34 sites in Japan
- Volunteers
- 443 people
- Sponsor
- Eli Lilly and Company
Diabetic Neuropathy, Painful
A Study in Painful Diabetic Neuropathy
This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not…
- Trial name
- COMBO-DN (NCT01089556)
- Testing
- Duloxetine, Pregabalin
- Where
- 54 sites in Australia, Canada and 14 more
- Volunteers
- 811 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
The main reason for this study is to compare the study drug tirzepatide to insulin glargine in participants with type 2 diabetes on metformin with or without a sulfonylurea.
- Trial name
- NCT04093752
- Testing
- Tirzepatide, Insulin Glargine
- Where
- 67 sites in Australia, China and 2 more
- Volunteers
- 917 people
- Sponsor
- Eli Lilly and Company
Clear Cell Renal Cell Carcinoma
ABEMA Alone or in COMBO With MK-6482
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT04627064
- Testing
- Abemaciclib, MK-6482
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Sexually Transmitted Diseases
Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).
- Trial name
- NCT04860505
- Testing
- Doxycycline, Biktarvy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emory University
Dental Pain
Dental Pain Study of Analgesics in Patients Undergoing Molar Removal
Accessing the efficacy and safety of pregabalin when used alone and in combo with acetaminophen in a dental pain model. To test whether pre-operative dose of pregabalin increases the time to significant post-operative pain (NRS ≥…
- Trial name
- NVK009-0001 (NCT03652818)
- Testing
- Pre-Op pregabalin, Post-Op pregabalin
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Nevakar, Inc.
Chronic Pain, Back Pain
Combining Mechanisms for Better Outcomes (COMBO)
To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.
- Trial name
- COMBO (NCT03689920)
- Testing
- Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
- Where
- 15 sites in United States
- Volunteers
- 174 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
Melanoma
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4…
- Trial name
- NCT01400451
- Testing
- Ipilimumab (BMS-734016), Vemurafenib
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Leukemia
Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)
The purpose of the study is to compare response rates in newly diagnosed Chronic Phase (CP) CML subjects treated with dasatinib plus BMS-833923 versus dasatinib alone.
- Trial name
- NCT01357655
- Testing
- Dasatinib, BMS-833923
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes
The purpose of this study is to compare reduction in A1C for subjects taking Saxagliptin and Metformin XR vs. uptitrated Metformin XR.
- Trial name
- SCORE (NCT00960076)
- Testing
- Saxagliptin, Metformin XR
- Where
- 35 sites in United States, Colombia and 3 more
- Volunteers
- 282 people
- Sponsor
- AstraZeneca